nach oben

Erschienen in:

26.04.2021 | original article

Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis

verfasst von: Tomaž Omerzu, MD, Jožef Magdič, MD, Radovan Hojs, MD, PhD, Uroš Potočnik, PhD, Mario Gorenjak, MBI, PhD, Tanja Hojs Fabjan, MD, PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 1-2/2024

Einloggen, um Zugang zu erhalten

Summary

Background

Multiple sclerosis is an inflammatory disorder of the central nervous system. Inflammation may create high susceptibility to subclinical atherosclerosis. The purpose of this study was to compare subclinical atherosclerosis and the role of inflammatory cytokines between the group of patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls matched for age and sex.

Methods

The study group consisted of 112 non-diabetic and non-hypertensive RRMS patients treated with disease modifying drugs (DMD) and the control group was composed of 51 healthy subjects. The common carotid artery (CCA) intima media thickness (IMT) was investigated. Serum levels of risk factors for atherosclerosis and inflammatory cytokines were also determined.

Results

The mean CCA IMT (0.572 ± 0.131 mm vs. 0.571 ± 0.114 mm) did not differ (p > 0.05) between patients and controls. The RRMS patients’ CCA IMT was significantly correlated with serum interleukin 6 (IL-6) (p = 0.027), high-sensitivity C-reactive protein (hs-CRP) (p = 0.027), cystatin C (p < 0.0005), glucose (p = 0.031), cholesterol (p = 0.008), LDL (p = 0.021), erythrocyte sedimentation rate (p = 0.001) and triglyceride (p = 0.018) level. We fitted generalized linear models in order to assess the relationship between CCA IMT and IL‑6 with adjustment for sex and age. The obtained results showed that adjusted for age (p < 0.001) and sex (p = 0.048) IL‑6 serum levels statistically significantly (p = 0.009) predict CCA IMT only in the RRMS group.

Conclusion

The findings of the present study suggest that when treated with DMD RRMS might not be an independent risk factor for early atherosclerosis presenting with arterial wall thickening; however, the results suggest a significant association of IL‑6 serum levels with CCA IMT only in the RRMS group.

Vorheriger Artikel The Vienna idiopathic intracranial hypertension database—An Austrian registry

Nächster Artikel Psychometric properties of the Turkish version of the fear avoidance components scale in patients with chronic pain related to musculoskeletal disorders

Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518. https://doi.org/10.1136/bmj.i3518.CrossRefPubMed

Solaro C, Ponzio M, Moran E, et al. The changing face of multiple sclerosis: prevalence and incidence in an aging population. Mult Scler. 2015;21:1244–50. https://doi.org/10.1177/1352458514561904.CrossRefPubMed

Lunde HMB, Assmus J, Myhr KM, et al. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88:621–5. https://doi.org/10.1136/jnnp-2016-315238.CrossRefPubMed

Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13:375–82. https://doi.org/10.1038/nrneurol.2017.33.CrossRefPubMed

Ranadive SM, Yan H, Weikert M, et al. Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc. 2012;44(2):238–43. https://doi.org/10.1249/MSS.0b013e31822d7997.CrossRefPubMed

Singh RB, Mengi SA, Xu YJ, et al. Pathogenesis of atherosclerosis: a multifactorial process. Exp Clin Cardiol. 2002;7:40–53.PubMedPubMedCentral

Roshanisefat H, Bahmanyar S, Hillert J, et al. Multiple sclerosis clinical course and cardiovascular disease risk—Swedish cohort study. Eur J Neurol. 2014;21:1353–e88. https://doi.org/10.1111/ene.12518.CrossRefPubMed

Christiansen CF. Risk of vascular disease in patients with multiple sclerosis: a review. Neurol Res. 2012;34(8):746–53. https://doi.org/10.1179/1743132812Y.0000000051.CrossRefPubMed

Thormann A, Magyari M, Koch-Henriksen N, et al. Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. J Neurol. 2016;263:2484–93. https://doi.org/10.1007/s00415-016-8295-9.CrossRefPubMed

10.

Marie RA, Reider N, Cohen J, et al. A systematic review of incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler. 2015;21:318–31. https://doi.org/10.1177/1352458514564485.CrossRef

11.

Manouchehrinia A, Tench CR, Maxted J, et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain. 2013;136(Pt7):2298–304. https://doi.org/10.1093/brain/awt139.CrossRefPubMedPubMedCentral

12.

Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74:1041–7. https://doi.org/10.1212/WNL.0b013e3181d6b125.CrossRefPubMedPubMedCentral

13.

Gisterå A, Hansson GK. The immunology of atherosclerosis. Nat Rev Nephrol. 2017;13:368–80. https://doi.org/10.1038/nrneph.2017.51.CrossRefPubMed

14.

Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302. https://doi.org/10.1002/ana.22366.CrossRefPubMedPubMedCentral

15.

Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.CrossRefPubMed

16.

Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the association between carotid artery atherosclerosis and coronary artery stenosis: a case control study. Circulation. 1990;82:1230–42. https://doi.org/10.1161/01.cir.82.4.1230.CrossRefPubMed

17.

Burdick L, Periti M, Salvaggio A, et al. Relation between carotid artery atherosclerosis and time on dialysis. A non-invasive study in vivo. Clin Nephrol. 1994;42:121–6.PubMed

18.

London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996;50:600–8. https://doi.org/10.1038/ki.1996.355.CrossRefPubMed

19.

Piggnoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399–406.CrossRef

20.

Kawagishi T, Nishizawa Y, Konishi T, et al. High-resolution B‑mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int. 1995;48(3):820–6. https://doi.org/10.1038/ki.1995.356.CrossRefPubMed

21.

Savage T, Clarke AL, Giles M, et al. Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. Nephrol Dial Transplant. 1998;13:2004–12. https://doi.org/10.1093/ndt/13.8.2004.CrossRefPubMed

22.

Pahor A, Hojs R, Gorenjak M, et al. Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol Int. 2006;27(2):119–23. https://doi.org/10.1007/s00296-006-0176-6.CrossRefPubMed

23.

Meyer-Moock S, Feng YS, Maeurer M, et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58. https://doi.org/10.1186/1471-2377-14-58.CrossRefPubMedPubMedCentral

24.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology. 1983;5:580–3. https://doi.org/10.1212/wnl.33.11.CrossRef

25.

Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–82. https://doi.org/10.1093/brain/122.5.871.CrossRefPubMed

26.

Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5(4):244–50. https://doi.org/10.1177/135245859900500409.CrossRefPubMed

27.

Piko N, Ekart R, Bevc S, et al. Atherosclerosis, epigenetic modifications, and arterial stiffness. Acta Medico-Biotechnica. 2017;10(2):10–7.CrossRef

28.

Simons PC, Algra A, Bots ML, et al. Common carotid intima-media thickness and arterial stiffness: indicators of cardiovascular risk in high-risk patients. The SMART Study (Second Manifestations of ARTerial disease). Circulation. 1999;100(9):951–7. https://doi.org/10.1161/01.cir.100.9.951.CrossRefPubMed

29.

Yuksel B, Koc P, Ozaydin Goksu E, et al. Is multiple sclerosis a risk factor for atherosclerosis? J Neuroradiol. 2019; https://doi.org/10.1016/j.neurad.2019.10.002.CrossRefPubMed

30.

Dagan A, Gringouz I, Kliers I, et al. Disability progression in multiple sclerosis is affected by the emergence of comorbid arterial hypertension. J Clin Neurol. 2016;12(3):345–50. https://doi.org/10.3988/jcn.2016.12.3.345.CrossRefPubMedPubMedCentral

31.

Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199–204. https://doi.org/10.1136/bmj.321.7255.199.CrossRefPubMedPubMedCentral

32.

Kirbis S, Breskvar UD, Sabovic M, et al. Inflammation markers in patients with coronary artery disease—comparison of intracoronary and systemic levels. Wien Klin Wochenschr. 2010;122:31–4. https://doi.org/10.1007/s00508-010-1343-z.CrossRefPubMed

33.

Ridker PM, Glynn RJ, Hennekens CH. C‑reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–11. https://doi.org/10.1161/01.cir.97.20.2007.CrossRefPubMed

34.

Alber HF, Suessenbacher A, Weidinger F. Die Rolle der Inflammation in der Pathophysiologie akuter Koronarsyndrome. Wien Klin Wochenschr. 2005;117(13/14):445–55. https://doi.org/10.1007/s00508-005-0399-7. The role of inflammation in the pathophysiology of acute coronary syndromes.CrossRefPubMed

35.

Kaneko R, Sawada S, Tokita A, et al. Serum cystatin C level is associated with carotid arterial wall elasticity in subjects with type 2 diabetes mellitus: a potential marker of early-stage atherosclerosis. Diabetes Res Clin Pract. 2018;139:43–51. https://doi.org/10.1016/j.diabres.2018.02.003.CrossRefPubMed

36.

Hartman J, Frishman W. Inflammation and atherosclerosis: a review of the role of Interleukin‑6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol Rev. 2014;22(3):147–51. https://doi.org/10.1097/CRD.0000000000000021.CrossRefPubMed

Titel: Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis
verfasst von: Tomaž Omerzu, MD
Jožef Magdič, MD
Radovan Hojs, MD, PhD
Uroš Potočnik, PhD
Mario Gorenjak, MBI, PhD
Tanja Hojs Fabjan, MD, PhD
Publikationsdatum: 26.04.2021
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 1-2/2024
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-021-01862-7

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2024

MUW researcher of the month

A novel set of Austrian reference unit costs for comprehensive societal perspectives consistent with latest European costing methods for economic evaluations

The positive effect of spermidine in older adults suffering from dementia after 1 year

The three pillars in treating antibody-mediated encephalitis

Sex differences in vision and hearing impairments across age and European regions

Seasonality of benign paroxysmal positional vertigo